MLYS Q2 2024 Earnings — Mineralys Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

MLYSMineralys Therapeutics, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$45M

Net Income

-$41M

EPS (Diluted)

$-0.83

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$2,872

Balance Sheet

Total Assets

$318M

Total Liabilities

$28M

Stockholders' Equity

$290M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$45M	-$16M	-187.1%
Net Income	-$41M	-$12M	-237.8%